From Benchside to Clinic: Applying Data for Improved Congenital Adrenal Hyperplasia-From Benchside to Clinic: Applying Data for Improved Congenital Adrenal Hyperplasia

From Benchside to Clinic: Applying Data for Improved Congenital Adrenal Hyperplasia

Video Transcription

Video Summary

In summary, the discussion revolved around possible advancements in the treatment of congenital adrenal hyperplasia (CAH) using various therapies, including modified release hydrocortisone, gene therapy, CRF antagonists, anti-adrenal androgens, and CRF inhibitors. These treatments aim to address the therapeutic challenges associated with glucocorticoid therapy, such as adverse effects and difficulty achieving optimal control. The cases presented involved pediatric and adult patients with CAH, highlighting the impact of advanced bone age, fertility issues, and hirsutism. The potential future therapies offer a promising outlook for improving the quality of life for individuals with CAH, optimizing control of adrenal hyperandrogenemia, and reducing glucocorticoid dosing. Advances such as CRF antagonists and gene therapy provide hope for more effective and tailored treatment approaches in the management of CAH.

Keywords

congenital adrenal hyperplasia

CAH treatment advancements

modified release hydrocortisone

gene therapy for CAH

CRF antagonists for CAH

anti-adrenal androgens therapy

CRF inhibitors for CAH

glucocorticoid therapy challenges

pediatric CAH cases

adult CAH cases


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274